BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 01:20PM GMT
Release Date Price: €41.2 (-2.83%)
Unidentified Analyst

Good morning, everyone. Welcome to the 39th Annual JPMorgan Healthcare Conference. My name is [Badi Shadler]. I'm a member of the JPMorgan healthcare investment banking team. Thank you for joining our next session this morning on BioXcel.

I'm going to hand it over to our next presenter, Vimal Mehta, CEO and Chairman of BioXcel. But before we start, I'd just like to remind everyone that we will have a Q&A session after prepared remarks. And you'll be able to submit a question to Vimal and the team through the blue submit a question button.

And with that, I'll hand it over to Vimal.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thanks, [Badi]. Good morning, everyone. I'm Vimal Mehta, I'm CEO of BioXcel Therapeutics, a clinical-stage company utilizing artificial intelligence platform to develop innovative and transformative medicines in neuroscience and immuno-oncology.

Can you please put the first slide, please? Can we go to the next slide? Before I begin, as a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot